secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2024-10-09T23:59:59+00:00
Accession:  0001104659-24-107327
Event type: leadership
Sentiment:  negative
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel CCO Matthew Wiley departs; severance includes 9-mo salary, consulting through 2024
--------------------------------------------------------------------------------

- Matthew Wiley (SVP, Chief Commercial Officer) separated on Oct 2, 2024; severance agreement signed Oct 3.
- Severance: 9 months base salary continuation, prorated 2024 bonus, 9 months COBRA reimbursement.
- Consulting agreement with Wiley's LLC at $330/hr, $7,500 retainer, runs through Dec 31, 2024.
- Standard release of claims and non-disparagement obligations included in separation agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465924107327/0001104659-24-107327-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465924107327/tm2425903d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-107327

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer